For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and the formulated version represents a genuine change. These novel therapies preserve the transthyretin protein, slowing its damaging build-up and lessening the burden of the disease . Patients are now reporting positive out